US20100303873A1 - Biodegradable single-phase cohesive hydrogels - Google Patents
Biodegradable single-phase cohesive hydrogels Download PDFInfo
- Publication number
- US20100303873A1 US20100303873A1 US12/746,639 US74663908A US2010303873A1 US 20100303873 A1 US20100303873 A1 US 20100303873A1 US 74663908 A US74663908 A US 74663908A US 2010303873 A1 US2010303873 A1 US 2010303873A1
- Authority
- US
- United States
- Prior art keywords
- crosslinking
- gel
- polymers
- biodegradable single
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/594—Mixtures of polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the invention relates to the field of crosslinked biodegradable hydrogels having esthetic applications, for example, or medicinal applications.
- periurethral injection for the treatment of urinary incontinence by sphincter insufficiency
- postsurgical injection for preventing peritoneal adhesions in particular
- injection for replacement of deficient biological fluids in the joints in particular for replacing deficient synovial fluid
- injection subsequent to surgery for far-sightedness by scleral incisions with a laser for example, of periurethral injection for the treatment of urinary incontinence by sphincter insufficiency, postsurgical injection for preventing peritoneal adhesions in particular, injection for replacement of deficient biological fluids (in the joints in particular for replacing deficient synovial fluid) and injection subsequent to surgery for far-sightedness by scleral incisions with a laser.
- the hydrogels used have to exhibit optimized properties in terms of persistence in vivo, of rheology and of viscosity in order to guarantee good “injectability”, these hydrogels being applied by injection using needles of variable sizes depending on the applications but which have to remain as fine as possible in order to minimize postinjection reactions.
- compositions based on permanent or very slowly biodegradable particles dispersed in an injection vector for example PMMA (polymethyl methacrylate) particles in a collagen gel (Artecoll), acrylic hydrogel particles in a crosslinked sodium hyaluronate gel (Dermalive, Dermadeep) or polylactic acid or polylactide (PLA) particles in an aqueous vector (New Fill, Sculptra, the PLA being resorbed in 1 to 4 years depending on the size of the particles).
- PMMA polymethyl methacrylate particles in a collagen gel
- Acrylic hydrogel particles in a crosslinked sodium hyaluronate gel Dermadeep
- PLA polylactic acid or polylactide
- biodegradable implants based on crosslinked or noncrosslinked polysaccharides essentially based on sodium hyaluronate.
- IPN interpenetrating polymer networks
- Si-IPN semi-interpenetrating polymer networks
- Patent application FR 2 733 427 describes compositions which comprise a continuous phase and a dispersed phase composed of insoluble fragments of a hydrogel.
- the aqueous continuous phase acts as vehicle for the injection of the fragments of the dispersed phase.
- the present invention makes it possible to solve these various disadvantages.
- the present invention consists of a biodegradable single-phase cohesive hydrogel, characterized in that it is composed of a homogeneous mixture of x identical or different polymers, crosslinked prior to their interpenetration by mixing, in the single-phase hydrogel form, said crosslinked polymers being insoluble in water and miscible with one another and x being between 2 and 5.
- cohesiveness and the single-phase nature of a gel according to the invention is understood to mean the property of said gel of retaining its stability and its unity without the possibility of separation of the constituent gels.
- mixing is understood to mean a juxtaposition of x polymers without creation of a covalent bond between them. Interactions take place between the various polymers due to the presence of polar groups and of the aqueous medium; these interactions are of the low energy weak bond type involving forces such as, for example, intermolecular hydrogen bridges, indeed even ionic bonds.
- the mixture thus obtained exhibits properties comparable to those of IPNs without being an IPN within the meaning of the IUPAC definition; this is because this definition excludes mixtures of networks crosslinked beforehand. In this instance, however, the cohesive and crosslinked beforehand gels are intimately mixed, generating weak interchain bonds between them.
- Such a product exhibits the advantages of IPN networks without the disadvantages of employing the latter and makes it possible, by virtue of the use of a different degree of crosslinking for each constituent gel (or an identical degree of crosslinking, if the gels have very different molecular weights), to create more or less dense networks before their final hydration and, after mixing, to obtain a product having rheological properties which can be “adjusted” by measuring the properties of the various constituent gels before the mixing.
- crosslinking reactions can thus be carried out on isolated polymers, thus avoiding the problems of selectivity.
- crosslinking conditions are simple, each gel being crosslinked independently of one another.
- the synergy is obtained as a result of the optimization of the two parameters which act mutually on one another, low crosslinking being favorable to the injectability and unfavorable to the persistence and high crosslinking being favorable to the persistence and, a contrario, unfavorable to the injectability.
- the respective properties of the networks complement one another; thus the gel with the highest elastic parameter will bring about an increase in the elastic parameter of the combination, in comparison with the least crosslinked gel.
- the gel with the lowest level of injectability will make it possible to reduce the level of injectability of the combination.
- the characteristics of the final mixture are thus optimized, with a synergy of the elastic and viscous parameters of the mixtures obtained, which can be modified according to the respective proportions of each of the constituent gels and the pathology targeted.
- the persistence of the gel will be known and predictable, apart from the factors of inter-individual variation, and the reproducibility of the injectability properties will make possible great control of the action and the elimination of a number of side effects.
- a hydrogel because of its makeup, will exhibit decomposition kinetics which depend on the number of gels mixed and on the degrees of crosslinking. This is because the decomposition kinetics depend on several parameters: the degree of crosslinking, the concentration of polymer and the molecular weights of the polymers used at the time of crosslinking.
- the decomposition kinetics will be slowed down: this is because to homogeneously mix gels with variable degrees of persistence will make it possible to strengthen the overall persistence by an effect of “diluting” the random cleavages of the gel via either free radicals or enzymes (hyaluronidases, and the like) present in the dermis or the biological fluid replaced.
- the finished product thus manufactured will thus be more persistent for equivalent levels of injectability, while remaining perfectly biodegradable.
- the persistence will also be optimized as a result of the interpenetration of the networks, increasing the density of crosslinks or chemical bonds while retaining the mechanical and chemical independence of the 2 to x crosslinked gels.
- random attack of the free radicals is statistically lower in comparison with a simple single-phase gel (just 1 network, faster weakening of the bonds at the surface, lower density of chemical bonds).
- Accessibility to the core of the gel will also be rendered much more difficult for decomposition by enzymes or via CD44 antigens.
- the use of different molecular weights in each single-phase gel crosslinked beforehand will make it possible to form networks with a more or less dense structure or meshwork and thus to further strengthen the persistence in vivo.
- the hydrogel according to the invention is characterized in that the polymers are selected from polysaccharides.
- the hydrogel according to the invention is characterized in that the polymers are selected from the group consisting of polylactic acids and their derivatives, N-vinylpyrrolidone, polyvinyl acids, polyacrylamides and acrylic polymers and biologically acceptable derivatives.
- the polysaccharides are selected from the group consisting of hyaluronic acid, keratan, heparin, cellulose and cellulose derivatives, alginic acid, xanthan, carrageenan, chitosan, chondroitin and their biologically acceptable salts.
- At least one of the x polysaccharides is selected from the group consisting of hyaluronic acid and its biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one of the x polysaccharides is selected from the group consisting of cellulose derivatives and their biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one the x polysaccharides is selected from the group consisting of chondroitin and its biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one of the x polysaccharides is selected from the group consisting of chitosan and its biologically acceptable salts and derivatives.
- polysaccharides which can be employed in the hydrogel according to the present invention are of any type known in the field and are preferably selected from those produced by bacterial fermentation.
- the polysaccharides which can be used in the context of the present invention exhibit a molecular weight MW of between approximately 0.02 and approximately 6 MDa, preferably of between approximately 0.04 and approximately 4 MDa and more preferably of between approximately 0.05 and approximately 3 MDa.
- hyaluronic acid and its salts especially its salts acceptable from the physiological viewpoint, such as the sodium, potassium or calcium salts, advantageously the sodium salt.
- chondroitin sulfate and its salts and cellulose derivatives such as hydroxypropylmethylcellulose or carboxymethylcellulose, and the mixtures of two or more of them.
- the constituent gels of the hydrogel according to the invention are preferably based on sodium hyaluronate.
- the x polymers are identical.
- the x polymers are different.
- the hydrogel according to the invention is characterized in that x is equal to 2.
- the first of the x polysaccharides is selected from the group consisting of hyaluronic acid and its salts, cellulose derivatives and their salts and xanthan and the second is selected from the group consisting of chondroitin sulfate and its salts, chitosan and its salts and derivatives, cellulose derivatives and their salts and alginic acids.
- the first of the x polymers is selected from the group consisting of hyaluronic acid and its salts, cellulose derivatives and their salts and xanthan and the second is selected from the group consisting of polylactic acids and their derivatives and acrylic derivatives.
- the first of the x polymers is selected from the group of sodium hyaluronate and the second is selected from the group consisting of chondroitin sulfate and its salts, chitosan and its salts and derivatives, cellulose derivatives and their salts and alginic acids.
- the ratio by weight of the highly crosslinked polysaccharide to the weakly crosslinked polysaccharide can vary within very wide proportions, according to the nature of the polysaccharides used, their respective degrees of crosslinking and also the final properties targeted.
- the proportion by weight of the highly crosslinked polysaccharide gel in the finished product is between approximately 0.1 and 99.9%, preferably from 5 to 50%, of gel 1 exhibiting a degree of crosslinking x1 and from 50 to 95% of gel 2 exhibiting a degree of crosslinking x2 or even more preferably from 10 to 40% of gel 1 exhibiting a degree of crosslinking x1 and from 60 to 90% of gel 2 exhibiting a degree of crosslinking x2.
- the invention also relates to the process for the preparation of a biodegradable hydrogel according to the invention; this process comprises a stage of developing specifications which fix the rheological properties targeted as a function of the applications.
- an elasticity is targeted, that resulting from the degree of crosslinking, and, for the determination of the injectability, the viscosity at a high shear rate, also related to the degree of crosslinking, is set; these parameters depend on the starting materials, in particular on their molecular weight.
- the process for the preparation of a biodegradable single-phase cohesive hydrogel according to the invention is characterized in that it comprises at least the stages of:
- the hydration is carried out, for example, by immersion in or addition of a buffered isotonic solution.
- the process additionally comprises x stages of crosslinking x polymers before mixing the x crosslinked polymers.
- the hydration is generally carried out in an aqueous medium by simple mixing of the mixture of crosslinked gels with an aqueous solution, advantageously a buffered physiological aqueous solution, so as to obtain a final concentration which can vary within very wide proportions according to the nature of the polysaccharides used, their respective degrees of crosslinking and also the use envisaged.
- the buffered solution which can be used can, for example, be an osmolar physiological solution exhibiting a pH of between approximately 6.8 and approximately 7.5.
- This final concentration of total polysaccharides is generally between approximately 5 and approximately 100 mg/g, preferably between approximately 5 and approximately 50 mg/g, for example approximately 20 mg/g, of hydrogel.
- the process of the present invention thus makes it possible to obtain a biodegradable single-phase cohesive hydrogel which can be injected and with a long lasting persistence.
- the two crosslinking stages are carried out in a medium having a pH value which is identical or different.
- Each of these stages can be carried out in an acidic or basic medium, preferably in a basic medium, for example at a pH of between 8 and 14, preferably between 8 and 13.
- crosslinking reactions employed in the process of the invention are reactions well known to a person skilled in the art.
- a person skilled in the art can develop and optimize the crosslinking conditions according to said polysaccharide and said crosslinking agent: degree of crosslinking, temperature, pH.
- degree of crosslinking degree of crosslinking
- temperature degree of crosslinking
- pH pH
- the crosslinking agents which are involved in the crosslinking stages are generally bi- or polyfunctional crosslinking agents of various types and can, for example, be selected from DVS (divinyl sulfone) in an alkaline medium (see U.S. Pat. No. 4,582,865), bi- or polyfunctional epoxy compounds (see U.S. Pat. No. 4,716,154), carbodiimides, or formaldehyde (see GB 2 151 244).
- BDDE 1,4-butanediol diglycidyl ether
- diepoxyoctane 1,2-bis(2,3-epoxypropyl)-2,3-ethylene.
- Preference is very particularly given to the use of 1,4-butanediol diglycidyl ether (BDDE) for each of the crosslinking stages.
- each of the crosslinking stages can be carried out with one or more crosslinking agents, it being possible for the latter to be identical or different in one or another of the stages, under the pH conditions indicated above.
- the polysaccharides can advantageously be purified according to conventional purification techniques (for example by washing with a continuous stream of water, dialysis baths, and others), in order to remove the unreacted residual crosslinking agent.
- crosslinking stages can advantageously be followed by a neutralization stage (i.e., neutralization as far as a pH value of approximately 7), for example by addition of an appropriate amount of 1N hydrochloric acid.
- a neutralization stage i.e., neutralization as far as a pH value of approximately 7
- the x polymers exhibit different degrees of crosslinking, at least one of the x polymers exhibiting a degree of crosslinking x1 and at least one of the x polymers exhibiting a degree of crosslinking x2, and x1 being greater than x2.
- the x polymers exhibit identical degrees of crosslinking, it being understood that the polymers can have different molecular weights.
- x1 and x2 are between 0.02 and 0.4 and preferably between 0.08 and 0.2.
- crosslinking it may be advantageous to neutralize the gel obtained according to standard processes known in the field, for example by addition of acid, when the crosslinking is carried out in a basic medium, and by addition of a base, when the crosslinking is carried out in an acidic medium.
- the mixture obtained on conclusion of the process can optionally be subjected to an additional hydration stage, in order to obtain a gel in the form of an injectable hydrogel suitable for the applications envisaged.
- the invention relates to the use of a hydrogel according to the invention in the formulation of a viscosupplementation composition.
- the invention relates to the use of a hydrogel according to the invention in the formulation of a composition for filling in wrinkles.
- the applications targeted are more particularly the applications commonly observed in the context of injectable polysaccharide viscoelastic products used or which can potentially be used in the following pathologies or treatments:
- the hydrogel according to the invention can be used:
- the hydrogel according to the invention also has an important application in joint surgery and in dental surgery for filling in periodontal pockets, for example.
- the hydrogel according to the invention can also have an entirely advantageous application as matrix for releasing one (or more) active principle(s) dispersed beforehand within it.
- active principle is understood to mean any product which is active pharmacologically: medicinal active principle, antioxidant active principle (sorbitol, mannitol, and the like), antiseptic active principle, anti-inflammatory active principle, local anesthetic active principle (lidocaine, and the like), and the like.
- the hydrogel according to the invention preferably after purification and hydration to give the hydrogel, can be packaged, for example in syringes, and sterilized according to any means known per se (for example by autoclaving) in order to be sold and/or used directly.
- the present invention relates to a kit comprising a hydrogel according to the invention packaged in a sterile syringe.
- x number of moles of crosslinking agent introduced into the reaction medium/total number of disaccharide units introduced into the reaction medium.
- Sodium hyaluronate fibers of injectable grade (1 g: molecular weight: approximately 2.7 MDa) are weighed out in a container.
- a 1% aqueous solution of sodium hydroxide in water (7.4 g) is added and the combined mixture is homogenized for approximately 1 hour using a spatula at ambient temperature and 900 mm Hg.
- BDDE noncrosslinked sodium hyaluronate
- NaHA noncrosslinked sodium hyaluronate
- the combined mixture is subsequently placed on a water bath at 50° C. for 2 h 20 in order to obtain a degree of crosslinking x1 of approximately 0.14.
- the crosslinked final gel is subsequently neutralized by addition of 1N HCl and placed in a phosphate buffer bath in order to stabilize the pH and to make possible its hydration or swelling as far as 30 mg/g of HA.
- An NaHa hydrogel crosslinked by the route conventionally used is thus obtained: G1 with an HA concentration of approximately 30 mg/g.
- a portion of the gel is stored at this concentration and the other portion is diluted by addition of phosphate buffer in order to obtain, at the end, 20 mg/g of HA.
- This gel is subsequently homogenized before being filled into syringes which are sterilized by autoclaving: sterile syringes comprising gel G1 at 20 mg/g.
- Sodium hyaluronate fibers of injectable grade (1 g; molecular weight: approximately 1.5 MDa) are weighed out and dried beforehand in a container.
- BDDE 43 mg
- NaHA noncrosslinked sodium hyaluronate
- the crosslinked final gel is subsequently neutralized by addition of 1N HCl and placed in a phosphate buffer bath in order to stabilize the pH and to make possible its hydration or swelling as far as 30 mg/g of HA.
- An NaHa hydrogel crosslinked by the route conventionally used is thus obtained: G2 with an HA concentration of approximately 30 mg/g.
- the mixture thus obtained is a homogeneous gel comprising 20 mg/g of HA and composed of 2 inter-penetrating networks; this gel is then packaged into syringes and autoclaved.
- the mixture thus obtained is a homogeneous gel comprising 20 mg/g of HA and composed of 2 inter-penetrating networks; this gel is then packaged into syringes and autoclaved.
- the half-lives of the interpenetrating networks of gels obtained according to the invention are longer, guaranteeing a greater time of in vivo persistence.
- the product of “two-phase” type shows, after centrifuging, separated particles at the bottom of the syringe. If the product is ejected from the syringe, the viscous product exits first, followed by the particles, which have no cohesiveness with one another, agglomerated at the bottom of the syringe, and which render the injectability particularly difficult.
- IPN-Like Gel 1 70% Gel 1 cross. x1+30% Gel 2 cross. x2
- IPN-Like Gel 2 50% Gel 1 cross. x1+50% Gel 2 cross. x2
- IPN-Like Gel 3 30% Gel 1 cross. x1+70% Gel 2 cross. x2
- the extrusion force is characterized on a Mecmesin tensile/compression testing machine under a rate of compression of 50 mm/min with 23G1 1 ⁇ 4 needles; the results are given in the table below.
- the elasticity is characterized on a TA Instruments AR2000 Ex rheometer in oscillation at 25° C., the value of the elasticity being recorded at a frequency of 1 Hz; the results are given in the table below.
- This stage is identical to stage a) of the synthesis of Gel 1 of example 1.
- This stage is identical to stage b) of the synthesis of Gel 1 of example 1, with 81 mg of BDDE.
- a Gel 3 with a degree of crosslinking x3 of approximately 0.17 is obtained.
- This stage is identical to stage c) of the synthesis of Gel 1 of example 1, in order to obtain a gel G3 with an HA concentration of approximately 30 mg/g.
- a portion of the gel is stored at this concentration and the other portion is diluted by addition of phosphate buffer in order to finally obtain 24 mg/g of HA; this gel is subsequently homogenized before being filled into syringes which are sterilized by autoclaving: sterile syringes comprising gel G3 at 24 mg/g.
- the mixture thus obtained is a homogeneous gel comprising 24 mg/g of HA and composed of 2 inter-penetrating networks; this gel is then packaged into syringes and autoclaved.
- stage c) of example 1 Identical to stage c) of example 1 with 41 mg of BDDE.
- the combined product is brought to 50° C. on a water bath for 3 hours, in order to obtain a degree of crosslinking x6 of approximately 0.09.
- Gel G7 composed of the interpenetration of the 3 crosslinked gels (G4, G5 and G6), has the lowest extrusion force, for an elasticity value greater by approximately 20% than that of the gel G6 with a close but slightly greater level of injectability.
- BDDE 37 mg is added to the noncrosslinked CMC gel obtained in the preceding stage, the combined mixture being homogenized with a spatula for approximately 30 minutes at ambient temperature. The combined mixture is subsequently placed on a water bath at 50° C. for 3 h in order to obtain a degree of crosslinking x8 of approximately 0.19.
- the crosslinked final gel is subsequently neutralized by addition of 1N HCl and placed in a phosphate buffer bath in order to stabilize the pH and to make possible its hydration or swelling as far as 45 mg/g of CMC.
- An NaCMC hydrogel crosslinked by the route conventionally used is thus obtained: G8 with a CMC concentration of approximately 45 mg/g.
- the HA gel G1 crosslinked to a level of 0.14, at a concentration of 30 mg/g, is added in various proportions to the crosslinked NaCMC gel G8, the phosphate buffer is added in order to adjust the final concentrations to 26 mg/g of HA and 37 mg/g of CMC and the 2 gels are placed under slow mechanical stirring with the phosphate buffer for 1 hour under hyperbaric pressure.
- 3 interpenetrating gels as described below are thus obtained:
- interpenetrating gels are subsequently packaged into syringes and characterized by rheology (elastic modulus G′) and by injectability under a rate of 13 mm/min with 27G1/2 needles.
- the gels G1 and G8 are also adjusted to the concentrations of 26 mg/g for G1 and 37 mg/g for G8 in order to compare them with the 3 interpenetrating gels.
- G1 G8 G9 G10 G11 cross- (cross- Interpene- Interpene- Interpene- Interpene- linked HA, linked CMC, trating gel trating gel trating gel 26 mg/g) 37 mg/g) 30% G1 + 70% G8 50% G1 + 50% G8 70% G1 + 30% G8 Elastic modulus 235 265 240 243 264 G′ at 1 Hz
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0759641A FR2924615B1 (fr) | 2007-12-07 | 2007-12-07 | Hydrogel cohesif biodegradable. |
FR0759641 | 2007-12-07 | ||
PCT/EP2008/067029 WO2009071697A1 (fr) | 2007-12-07 | 2008-12-08 | Hydrogel cohésif monophasique biodégradable |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/067029 A-371-Of-International WO2009071697A1 (fr) | 2007-12-07 | 2008-12-08 | Hydrogel cohésif monophasique biodégradable |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/164,592 Continuation US9919076B2 (en) | 2007-12-07 | 2014-01-27 | Biodegradable single-phase cohesive hydrogels |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100303873A1 true US20100303873A1 (en) | 2010-12-02 |
Family
ID=39473297
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/746,639 Abandoned US20100303873A1 (en) | 2007-12-07 | 2008-12-08 | Biodegradable single-phase cohesive hydrogels |
US14/164,592 Active US9919076B2 (en) | 2007-12-07 | 2014-01-27 | Biodegradable single-phase cohesive hydrogels |
US15/812,588 Active US10207024B2 (en) | 2007-12-07 | 2017-11-14 | Biodegradable single-phase cohesive hydrogels |
US16/249,606 Abandoned US20190167844A1 (en) | 2007-12-07 | 2019-01-16 | Biodegradable single-phase cohesive hydrogels |
US17/364,081 Pending US20210322636A1 (en) | 2007-12-07 | 2021-06-30 | Biodegradable single-phase cohesive hydrogels |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/164,592 Active US9919076B2 (en) | 2007-12-07 | 2014-01-27 | Biodegradable single-phase cohesive hydrogels |
US15/812,588 Active US10207024B2 (en) | 2007-12-07 | 2017-11-14 | Biodegradable single-phase cohesive hydrogels |
US16/249,606 Abandoned US20190167844A1 (en) | 2007-12-07 | 2019-01-16 | Biodegradable single-phase cohesive hydrogels |
US17/364,081 Pending US20210322636A1 (en) | 2007-12-07 | 2021-06-30 | Biodegradable single-phase cohesive hydrogels |
Country Status (18)
Country | Link |
---|---|
US (5) | US20100303873A1 (fr) |
EP (2) | EP2572702B1 (fr) |
JP (2) | JP5571562B2 (fr) |
KR (1) | KR101597333B1 (fr) |
CN (1) | CN101925348B (fr) |
AU (1) | AU2008333132B2 (fr) |
BR (1) | BRPI0821046B1 (fr) |
CA (1) | CA2708023C (fr) |
EA (1) | EA022478B1 (fr) |
ES (2) | ES2526081T3 (fr) |
FR (1) | FR2924615B1 (fr) |
HK (1) | HK1150772A1 (fr) |
IL (1) | IL206166A (fr) |
MX (1) | MX2010006248A (fr) |
PL (2) | PL2572702T3 (fr) |
PT (2) | PT2572702E (fr) |
UA (1) | UA99161C2 (fr) |
WO (1) | WO2009071697A1 (fr) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130196944A1 (en) * | 2010-08-19 | 2013-08-01 | Merz Pharma Gmbh & Co. Kgaa | Filler composition comprising beta-glucans |
US20130237615A1 (en) * | 2010-12-06 | 2013-09-12 | Teoxane | Process of preparing a crosslinked gel |
WO2013185934A1 (fr) | 2012-06-15 | 2013-12-19 | Merz Pharma Gmbh & Co. Kgaa | Procédé de préparation d'une composition à base d'acide hyaluronique |
US9155757B2 (en) | 2013-10-07 | 2015-10-13 | Laboratoires Vivacy | Methods and kits for treating vaginal and vulvar vestibule mucosa disorders |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
KR20160031465A (ko) * | 2013-06-11 | 2016-03-22 | 앙테이스 에스.아. | 하이알루론산의 가교 방법, 주사용 하이드로젤의 제조방법, 수득한 하이드로젤 및 수득한 하이드로젤의 용도 |
US9314530B2 (en) | 2012-06-13 | 2016-04-19 | Laboratoires Vivacy | Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
US9402799B2 (en) | 2012-08-29 | 2016-08-02 | Laboratories Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
DE102017121831A1 (de) | 2016-09-22 | 2018-03-22 | Ford Global Technologies, Llc | System und Verfahren zum Verlängern der Betriebszeit von Ventilaktoren eines Verbrennungsmotors |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
US10500225B2 (en) | 2015-12-07 | 2019-12-10 | Kh Medtech Sárl | Injectable composition; method for preparing said composition; use of said composition |
US10588922B2 (en) | 2015-06-24 | 2020-03-17 | Kylane Laboratoires Sa | Method for preparing an injectable cross-linked hydrogel, hydrogel obtained; and use of the obtained hydrogel |
CN114129470A (zh) * | 2016-02-12 | 2022-03-04 | 罗丹菲尔茨有限责任公司 | 保湿组合物及其用途 |
US11492433B2 (en) * | 2018-04-23 | 2022-11-08 | Ngk Spark Plug Co., Ltd. | Hydrogel and method for producing hydrogel |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
CA2687990A1 (fr) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Collagene reticule et utilisations de ce dernier |
US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8114898B2 (en) | 2007-11-16 | 2012-02-14 | Allergan, Inc. | Compositions and methods for treating purpura |
US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
FR2938187B1 (fr) † | 2008-11-07 | 2012-08-17 | Anteis Sa | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur |
IT1395392B1 (it) * | 2009-08-27 | 2012-09-14 | Fidia Farmaceutici | Geli viscoelastici come nuovi filler |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
CA2792729C (fr) | 2010-03-12 | 2016-06-28 | Allergan Industrie, Sas | Composition fluide pour l'amelioration d'etats cutanes |
EP2550027B2 (fr) | 2010-03-22 | 2019-03-20 | Allergan, Inc. | Hydrogels réticulés à base de polysaccharides et de protéines- polysaccharides pour l'augmentation des tissus mous |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
CN107412002A (zh) | 2011-06-03 | 2017-12-01 | 阿勒根公司 | 包括抗氧化剂的皮肤填充剂组合物 |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
KR101421933B1 (ko) * | 2012-06-19 | 2014-07-28 | 서울과학기술대학교 산학협력단 | 생분해성 하이브리드 하이드로젤 및 그 제조방법 |
WO2014198406A1 (fr) | 2013-06-11 | 2014-12-18 | Anteis S.A. | Procédé de réticulation de l'acide hyaluronique, procédé de préparation d'un hydrogel injectable, hydrogel obtenu et utilisation de l'hydrogel obtenu |
FR3015290B1 (fr) | 2013-12-23 | 2017-01-13 | Lab Vivacy | Compositions d'acide hyaluronique compreant de la mepivacaine |
AR099900A1 (es) | 2014-04-01 | 2016-08-24 | Merz Pharma Gmbh & Co Kgaa | Rellenos para tejidos blandos con polisacáridos con persistencia mejorada, kit, procedimiento, uso |
CN104086788B (zh) * | 2014-07-17 | 2016-08-17 | 华熙福瑞达生物医药有限公司 | 一种注射用修饰透明质酸钠凝胶 |
EP3620184A1 (fr) | 2014-09-30 | 2020-03-11 | Allergan Industrie, SAS | Compositions d'hydrogel stables comprenant des additifs |
TWI716365B (zh) * | 2014-11-13 | 2021-01-21 | 德商梅茲製藥有限兩合公司 | 注射型真皮填充劑組合物及其套組、製備方法、與使用 |
EP3040117A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de sulfate de chondroïtine réticulée par éther et leur utilisation pour des applications de tissu mou |
EP3040118A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de chondroïtine réticulée d'éther et leur utilisation pour des applications de tissu mou |
WO2016128783A1 (fr) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions et méthodes pour améliorer l'apparence de la peau |
CN104771331B (zh) * | 2015-03-12 | 2017-12-12 | 华熙福瑞达生物医药有限公司 | 一种透明质酸弹性体及其应用 |
FR3036035B1 (fr) | 2015-05-11 | 2018-10-05 | Laboratoires Vivacy | Compositions comprenant au moins un polyol et au moins un anesthesique |
WO2017102001A1 (fr) | 2015-12-16 | 2017-06-22 | Vplus International Sa | Composition d'acide hyaluronique pour injections peniennes |
US10722443B2 (en) | 2016-09-14 | 2020-07-28 | Rodan & Fields, Llc | Moisturizing compositions and uses thereof |
FR3047666A1 (fr) | 2016-02-15 | 2017-08-18 | Benedicte Vincente Gavard Molliard Tauzin | Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition |
KR101710639B1 (ko) * | 2016-06-07 | 2017-03-08 | 주식회사 파마리서치프로덕트 | 핵산, 키토산 및 히알루론산을 포함하는 조직 증강용 충전 조성물 및 이의 제조방법 |
FR3058064B1 (fr) | 2016-10-28 | 2020-08-07 | Lab Vivacy | Composition a base d'acide hyaluronique comprenant de la mepivacaine |
JP6939607B2 (ja) * | 2017-03-27 | 2021-09-22 | Jsr株式会社 | 組成物およびその用途 |
CN108250462A (zh) * | 2017-05-08 | 2018-07-06 | 上海利康瑞生物工程有限公司 | 一种抗酶解交联透明质酸钠凝胶及其制备方法和制剂 |
WO2018220283A1 (fr) | 2017-05-29 | 2018-12-06 | Kh Medtech Sarl | Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine |
KR101944008B1 (ko) | 2017-09-18 | 2019-01-30 | (주) 제이씨바이오 | 히알루론산을 포함하는 투명 하이드로겔 막 및 이를 이용한 콘택트렌즈 |
FR3072026B1 (fr) * | 2017-10-10 | 2019-10-25 | Capsum | Ensembles de particules, procedes de preparation et kits les comprenant |
US11884765B2 (en) | 2018-04-04 | 2024-01-30 | Board Of Regents, The University Of Texas System | Biodegradable elastic hydrogels for bioprinting |
WO2020095079A1 (fr) * | 2018-11-06 | 2020-05-14 | Kylane Laboratoires Sa | Composition injectable contenant de l'acide hyaluronique pour des applications au niveau du corps |
LU101045B1 (en) | 2018-12-11 | 2020-06-11 | Qventis GmbH | Method for the manufacture and use of a bionic hydrogel composition for medical applications |
FR3095206B1 (fr) | 2019-04-17 | 2021-11-05 | Lab Vivacy | Procede de reticulation d’un polymere |
CN111249172A (zh) * | 2020-01-15 | 2020-06-09 | 陈勇 | 一种美容注射凝胶及其制备方法 |
EP3854377A1 (fr) * | 2020-01-22 | 2021-07-28 | Laboratoires Genevrier Sas | Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose |
FR3111903B1 (fr) | 2020-06-24 | 2022-12-02 | Lab Vivacy | Procede d’incorporation de composes organiques en solution au sein d’un hydrogel |
EP4199980A1 (fr) * | 2020-08-18 | 2023-06-28 | Innate S.r.l. | Composition injectable et utilisation de ladite composition |
FR3113522A1 (fr) | 2020-08-20 | 2022-02-25 | Laboratoires Vivacy | procédé d’évaluation des caractéristiques rhéologiques d’un gel |
WO2023064618A1 (fr) * | 2021-10-15 | 2023-04-20 | Prohibix Llc | Précipités d'acide hyaluronique réticulé |
WO2023107199A1 (fr) | 2021-12-09 | 2023-06-15 | L'oreal | Compositions cosmétiques correctrices de peau et leurs méthodes d'utilisation |
FR3132220B1 (fr) | 2022-01-31 | 2024-02-02 | Oreal | compositions cosmétiques perfectrices de peau et procédés d’utilisation |
FR3130131B1 (fr) | 2021-12-09 | 2023-11-17 | Oreal | Dispersion comprenant une particule polymerique, un agent stabilisant a groupe cycloalkyle, une huile, et un polyol, procede de traitement des matieres keratiniques mettant en œuvre la dispersion |
FR3130132B1 (fr) | 2021-12-09 | 2023-11-17 | Oreal | Dispersion comprenant une particule polymerique, un agent stabilisant a groupe cycloalkyle, une huile, et de l’eau, procede de traitement des matieres keratiniques mettant en œuvre la dispersion |
FR3135399A1 (fr) | 2022-03-30 | 2023-11-17 | Laboratoires Vivacy | émulsion comprenant un hydrogel et de la graisse ou un dérivé de graisse |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
US6921819B2 (en) * | 2000-07-19 | 2005-07-26 | Laboratoires D'esthetique Appliquee | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof |
WO2005085329A1 (fr) * | 2004-02-03 | 2005-09-15 | Anteis S.A. | Gel reticule biocompatible |
US20060194758A1 (en) * | 2003-04-10 | 2006-08-31 | Pierre Lebreton | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
US20070192426A1 (en) * | 2002-09-17 | 2007-08-16 | Bellsouth Intellectual Property Corporation | Extending Functionality of Workflow applications using Instant Messaging (IM) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1238043A (fr) | 1983-12-15 | 1988-06-14 | Endre A. Balazs | Preparations d'acide hyaluronique insolubles dans l'eau et procede de production |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
IT1260154B (it) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn) |
FR2733426B1 (fr) | 1995-04-25 | 1997-07-18 | Debacker Yves | Dispositif medical pour le comblement des deformations du volume de la peau telles que rides et cicatrices par injection de 2 formes physico-chimiques differentes d'un polymere biologique |
FR2733427B1 (fr) * | 1995-04-25 | 2001-05-25 | W K Et Associes | Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique |
JP3538741B2 (ja) * | 1995-05-23 | 2004-06-14 | 独立行政法人 科学技術振興機構 | 複合刺激応答型生体内分解性高分子ヒドロゲル |
CN1161127C (zh) | 1997-07-03 | 2004-08-11 | 奥奎斯特公司 | 交联的多糖药物载体 |
FR2780730B1 (fr) * | 1998-07-01 | 2000-10-13 | Corneal Ind | Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique |
GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
WO2003093327A1 (fr) * | 2002-05-01 | 2003-11-13 | Hokkaido Technology Licensing Office Co., Ltd. | Gel ayant une structure multiple en réseau et procédé de production |
GB0329907D0 (en) * | 2003-12-23 | 2004-01-28 | Innomed Ltd | Compositions |
US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
EP1750769B1 (fr) * | 2004-05-20 | 2013-01-23 | Mentor Worldwide LLC | Procede de preparation d'hydrogels polymeres injectables |
US8025696B2 (en) | 2004-06-18 | 2011-09-27 | National University Corporation Hokkaido University | Artificial meniscus and process of making thereof |
JP2006013612A (ja) * | 2004-06-22 | 2006-01-12 | Traffic Shimu:Kk | データ監視システム、プログラム、記録媒体、表示操作方法 |
US20060105022A1 (en) * | 2004-11-15 | 2006-05-18 | Shiseido Co., Ltd. | Process for preparing crosslinked hyaluronic acid gel |
CN1302050C (zh) * | 2005-07-07 | 2007-02-28 | 复旦大学 | 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用 |
EP1934289A4 (fr) * | 2005-09-09 | 2011-07-20 | Ottawa Health Research Inst | Alliages ipn, et procedes et compositions associes |
-
2007
- 2007-12-07 FR FR0759641A patent/FR2924615B1/fr not_active Expired - Fee Related
-
2008
- 2008-12-08 EA EA201070696A patent/EA022478B1/ru not_active IP Right Cessation
- 2008-12-08 ES ES12196144.5T patent/ES2526081T3/es active Active
- 2008-12-08 PL PL12196144T patent/PL2572702T3/pl unknown
- 2008-12-08 BR BRPI0821046A patent/BRPI0821046B1/pt active IP Right Grant
- 2008-12-08 US US12/746,639 patent/US20100303873A1/en not_active Abandoned
- 2008-12-08 PT PT121961445T patent/PT2572702E/pt unknown
- 2008-12-08 AU AU2008333132A patent/AU2008333132B2/en active Active
- 2008-12-08 CA CA2708023A patent/CA2708023C/fr active Active
- 2008-12-08 UA UAA201008468A patent/UA99161C2/ru unknown
- 2008-12-08 EP EP12196144.5A patent/EP2572702B1/fr active Active
- 2008-12-08 CN CN2008801256588A patent/CN101925348B/zh active Active
- 2008-12-08 MX MX2010006248A patent/MX2010006248A/es active IP Right Grant
- 2008-12-08 PL PL08858227T patent/PL2231108T3/pl unknown
- 2008-12-08 EP EP08858227.5A patent/EP2231108B1/fr active Active
- 2008-12-08 JP JP2010536490A patent/JP5571562B2/ja active Active
- 2008-12-08 ES ES08858227.5T patent/ES2538999T3/es active Active
- 2008-12-08 PT PT88582275T patent/PT2231108E/pt unknown
- 2008-12-08 WO PCT/EP2008/067029 patent/WO2009071697A1/fr active Application Filing
- 2008-12-08 KR KR1020107014771A patent/KR101597333B1/ko active IP Right Grant
-
2010
- 2010-06-03 IL IL206166A patent/IL206166A/en active IP Right Grant
-
2011
- 2011-05-17 HK HK11104897.3A patent/HK1150772A1/xx unknown
-
2014
- 2014-01-27 US US14/164,592 patent/US9919076B2/en active Active
- 2014-06-25 JP JP2014130602A patent/JP5883076B2/ja active Active
-
2017
- 2017-11-14 US US15/812,588 patent/US10207024B2/en active Active
-
2019
- 2019-01-16 US US16/249,606 patent/US20190167844A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,081 patent/US20210322636A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
US6921819B2 (en) * | 2000-07-19 | 2005-07-26 | Laboratoires D'esthetique Appliquee | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof |
US20070192426A1 (en) * | 2002-09-17 | 2007-08-16 | Bellsouth Intellectual Property Corporation | Extending Functionality of Workflow applications using Instant Messaging (IM) |
US20060194758A1 (en) * | 2003-04-10 | 2006-08-31 | Pierre Lebreton | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained |
WO2005085329A1 (fr) * | 2004-02-03 | 2005-09-15 | Anteis S.A. | Gel reticule biocompatible |
US8052990B2 (en) * | 2004-02-03 | 2011-11-08 | Anteis S.A. | Biocompatible crosslinked gel |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
Non-Patent Citations (2)
Title |
---|
American Academy of Orthopaedic Surgeons (AAOS) "Viscosupplementation Treatment for Arthritis" 2009 http://orthoinfo.aaos.org/topic.cfm?topic=a00217 * |
Espacenet English language machine translation of FR 2733427, published October 31, 1996, IDS reference filed June 7, 2010, 2013 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US20150335784A1 (en) * | 2010-08-19 | 2015-11-26 | Merz Pharma Gmbh & Co. Kgaa | Filler composition comprising beta-glucans |
US20130196944A1 (en) * | 2010-08-19 | 2013-08-01 | Merz Pharma Gmbh & Co. Kgaa | Filler composition comprising beta-glucans |
US9393189B2 (en) * | 2010-12-06 | 2016-07-19 | Teoxane | Process of preparing a crosslinked gel |
US20130237615A1 (en) * | 2010-12-06 | 2013-09-12 | Teoxane | Process of preparing a crosslinked gel |
KR20130132510A (ko) * | 2010-12-06 | 2013-12-04 | 테옥산 | 가교된 겔의 제조 공정 |
KR101868183B1 (ko) * | 2010-12-06 | 2018-06-15 | 테옥산 | 가교된 겔의 제조 공정 |
EP2649101B1 (fr) | 2010-12-06 | 2021-06-02 | Teoxane | Procédé de préparation d'un gel réticulé |
AU2011340106B2 (en) * | 2010-12-06 | 2016-03-03 | Teoxane | Process of preparing a cross linked gel |
US9314530B2 (en) | 2012-06-13 | 2016-04-19 | Laboratoires Vivacy | Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate |
EP2861626B1 (fr) * | 2012-06-15 | 2018-12-19 | Merz Pharma GmbH & Co. KGaA | Procédé de préparation d'une composition à base d'acide hyaluronique |
WO2013185934A1 (fr) | 2012-06-15 | 2013-12-19 | Merz Pharma Gmbh & Co. Kgaa | Procédé de préparation d'une composition à base d'acide hyaluronique |
US9402799B2 (en) | 2012-08-29 | 2016-08-02 | Laboratories Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
US10058499B2 (en) | 2012-08-29 | 2018-08-28 | Laboratoires Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
KR102256061B1 (ko) | 2013-06-11 | 2021-05-25 | 앙테이스 에스.아. | 하이알루론산의 가교 방법, 주사용 하이드로젤의 제조방법, 수득한 하이드로젤 및 수득한 하이드로젤의 용도 |
US20160144043A1 (en) * | 2013-06-11 | 2016-05-26 | Anteis S.A. | Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel |
KR20160031465A (ko) * | 2013-06-11 | 2016-03-22 | 앙테이스 에스.아. | 하이알루론산의 가교 방법, 주사용 하이드로젤의 제조방법, 수득한 하이드로젤 및 수득한 하이드로젤의 용도 |
US9782490B2 (en) * | 2013-06-11 | 2017-10-10 | Anteis S.A. | Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel |
US10010483B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
US9579257B2 (en) | 2013-08-20 | 2017-02-28 | Anutra Medical, Inc. | Haptic feedback and audible output syringe |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US10010482B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Syringe fill system and method |
US9155757B2 (en) | 2013-10-07 | 2015-10-13 | Laboratoires Vivacy | Methods and kits for treating vaginal and vulvar vestibule mucosa disorders |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
US10588922B2 (en) | 2015-06-24 | 2020-03-17 | Kylane Laboratoires Sa | Method for preparing an injectable cross-linked hydrogel, hydrogel obtained; and use of the obtained hydrogel |
US10500225B2 (en) | 2015-12-07 | 2019-12-10 | Kh Medtech Sárl | Injectable composition; method for preparing said composition; use of said composition |
CN114129470A (zh) * | 2016-02-12 | 2022-03-04 | 罗丹菲尔茨有限责任公司 | 保湿组合物及其用途 |
DE102017121831A1 (de) | 2016-09-22 | 2018-03-22 | Ford Global Technologies, Llc | System und Verfahren zum Verlängern der Betriebszeit von Ventilaktoren eines Verbrennungsmotors |
US11492433B2 (en) * | 2018-04-23 | 2022-11-08 | Ngk Spark Plug Co., Ltd. | Hydrogel and method for producing hydrogel |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10207024B2 (en) | Biodegradable single-phase cohesive hydrogels | |
KR101514831B1 (ko) | 히알루론산 또는 그의 염 중 하나, 폴리올 및 리도카인의 가열 멸균된 주사용 조성물 | |
JP6660469B2 (ja) | ヒアルロン酸誘導体およびdna分画物が含まれているヒアルロン酸注射用組成物およびその利用 | |
TWI789338B (zh) | 原位可交聯的多醣組合物之用途、關聯於其之多筒注射系統、用於形成原位可交聯的多醣組合物之衍生物之組合及用於形成原位可交聯的多醣組合物之套組 | |
JP6476120B2 (ja) | 治療的使用のための架橋ヒアルロン酸及びハイドロキシアパタイトに基づく注入用無菌水性製剤 | |
CN113164652B (zh) | 具有优异的填充剂性能的包含透明质酸水凝胶的填充剂 | |
US8574629B2 (en) | Injectable hydrogel with an enhanced remanence and with an enhanced ability to create volume | |
EA026886B1 (ru) | Способ одновременного замещения и сшивки полисахарида по его гидроксильным функциональным группам | |
TWI683674B (zh) | 具有改良抗性之多糖軟組織充填劑 | |
JP2015526489A (ja) | 少なくとも1種のヒアルロン酸及びリン酸アスコルビルマグネシウムを含有する滅菌組成物 | |
KR20180122758A (ko) | 히알루론산을 기본으로 하는 조성물의 제조 방법 | |
CN107522881B (zh) | 制备单相修饰透明质酸钠凝胶的方法 | |
EA031349B1 (ru) | Композиция гиалуроновой кислоты, включающая мепивакаин | |
EP3316911A1 (fr) | Procédé de préparation de composition à base d'acide hyaluronique | |
RU2779473C1 (ru) | Наполнитель, имеющий прекрасные свойства наполнителя, содержащий гидрогель гиалуроновой кислоты | |
IT202100012737A1 (it) | Miscele di polisaccaridi e poliamminosaccaridi con proprietà reologiche migliorate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LABORATOIRES VIVACY, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIRON, ESTELLE MARIE;VITALLY, GUY;REEL/FRAME:024859/0152 Effective date: 20100622 |
|
AS | Assignment |
Owner name: LABORATOIRES VIVACY, FRANCE Free format text: CHANGE OF ADDRESS;ASSIGNOR:LABORATOIRES VIVACY;REEL/FRAME:030601/0943 Effective date: 20130220 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |